Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04753840
Status:
UNKNOWN
Last Update Posted:
2022-08-05
First Post:
2021-02-10
Brief Title:
Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension
Sponsor:
Henan Institute of Cardiovascular Epidemiology
Organization:
Henan Institute of Cardiovascular Epidemiology
Study Overview
Official Title:
Long-term of Remote Ischemic Preconditioning in Patients With Mild Hypertension
Status:
UNKNOWN
Status Verified Date:
2022-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
According to the latest survey data of China hypertension annual meeting there are about 300 million patients with hypertension in China with 10 million new cases of hypertension each year and there is an obvious trend of younger people In particular young and middle-aged people are in a state of mild hypertension for a long time which causes great pressure on health and medical treatment At present the main clinical measures for mild hypertension are to change their eating habits quit smoking and alcohol exercise and other lifestyle changes as well as drug control For most patients with mild hypertension drug control is not the best choice It has been reported that remote ischemic preconditioning RIPC may play an effective role in reducing blood pressure The purpose of this study was to investigate the extent of long-term application of RIPC to reduce blood pressure in patients with mild hypertension
Detailed Description:
A total of 200 patients with mild hypertension were enrolled in this study using the method of open label and parallel grouping 100 cases in the experimental group and 100 cases in the control group The experimental group was divided into life intervention drug group and life intervention ripc group with 50 patients in each group The results of 24-hour ambulatory blood pressure monitoring ABPM of the three groups were observed before and 3 months after use including HR pulse pressure 24-hour systolic blood pressure 24-hour diastolic blood pressure daytime systolic blood pressure daytime diastolic blood pressure nighttime systolic blood pressure and nighttime diastolic blood pressure The changes of renalase catecholamine renin angiotensin - Ⅱ aldosterone RhoA kinase no adenosine and bradykinin were observed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None